Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Doug Kline

Doug Kline

Senior Scientist II Abbvie

Seminars

Monday 12th October 2026

Assessing Immunogenic Senescence to Promote the Activity of Topo1 Inhibitor ADCs

2:30 pm

Exploring how Topo1 and Topo1- ADCs elicit immunogenic cell stress in vivo through the induction of cellular senescence
Delineating the host immune cell requirements for Topo1-induced immunogenicity
Identifying biomarkers of immunogenic cell stress mediated by Topo1 ADCs

Doug Kline - Speaker at 17th World ADC San Diego Summit

View all Speakers

View Event Brochure